Harmony Biosciences Holdings (HRMY) Gross Profit (2020 - 2026)

Harmony Biosciences Holdings has disclosed Gross Profit across 7 years of filings, most recently posting $170.9 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $170.9 million, up 11.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $688.2 million (up 17.95% YoY), and the FY2025 annual result was $670.1 million, up 20.11% from the prior year.
• Gross Profit came in at $170.9 million for Q1 2026 at Harmony Biosciences Holdings, down from $175.2 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $179.8 million in Q3 2025 to a low of $70.6 million in Q1 2022.
• The 5-year median for Gross Profit is $128.0 million (2023), against an average of $130.2 million.
• Across the five-year window, Gross Profit surged 44.12% in 2022 and grew 11.87% in 2026, its largest moves.
• Harmony Biosciences Holdings' Gross Profit stood at $101.4 million in 2022, then climbed by 23.5% to $125.3 million in 2023, then gained by 17.24% to $146.9 million in 2024, then grew by 19.32% to $175.2 million in 2025, then decreased by 2.49% to $170.9 million in 2026.
• The last three Gross Profit figures came in at $170.9 million (Q1 2026), $175.2 million (Q4 2025), and $179.8 million (Q3 2025), per Business Quant data.